Clinical trials: CMV
CMV Infection
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant…
- Trial name
- CY-CMV-2020 (NCT05315882)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Cytomegalovirus (CMV)
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV…
- Trial name
- NCT02931539
- Testing
- Maribavir, Ganciclovir, Valganciclovir
- Where
- 134 sites in United States, Australia and 12 more
- Volunteers
- 352 people
- Sponsor
- Shire
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
CMV
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant…
- Trial name
- NCT01769170
- Testing
- Brincidofovir
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 452 people
- Sponsor
- Jazz Pharmaceuticals
CMV Viremia, Transplantation Infection
CMV Infection and Immune Intervention After Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT.
- Trial name
- NCT04320303
- Testing
- expanded NK cells
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cytomegalovirus (CMV)
Study of SHP620 (Maribavir) in Healthy Adults
The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan).
- Trial name
- NCT02775240
- Testing
- Digoxin, Maribavir, Dextromethorphan
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shire
Cytomegalovirus (CMV)
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with…
- Trial name
- NCT01611974
- Testing
- Maribavir
- Where
- 32 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shire
Acute Hepatitis A, Acute Hepatitis B
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.
- Conditions
- Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C, Acute Hepatitis E
- Trial name
- NCT00755950
- Testing
- Silymarin, Lactose monohydrate
- Where
- 3 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore
Heart Transplant Infection, CMV Infection
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
This study evaluates the efficacy and safety of an individualized preventive strategy against CMV infection in CMV seropositive heart transplant patients based on the specific basal response of the lymphocytes againts CMV…
- Trial name
- ELISPOT-TC (NCT04278547)
- Testing
- ELISPOT IFN-γ assay
- Where
- Spain
- Volunteers
- 188 people
- Sponsor
- Hospital Universitari de Bellvitge
CMV DNAemia Pre-engraftment
Pre-engraftment Cytomegalovirus DNAemia
Cytomegalovirus (CMV) DNAemia occurs frequently in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients.Both high-level and persistent virus DNAemia are known risk factors for CMV end-organ disease and perhaps…
- Trial name
- NCT03889028
- Where
- Spain
- Volunteers
- 878 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Acute Leukemia, CMV Viremia
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
- Conditions
- Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04298502
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
CMV
Clinical Evaluation of the QuantiFERON CMV Assay
Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
- Trial name
- NCT03502161
- Testing
- QuantiFERON CMV Assay
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Quantiferon-CMV, Cytomegalovirus Infections
Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients
Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.
- Conditions
- Quantiferon-CMV, Cytomegalovirus Infections, Kidney Transplant Infection, Hemodialysis
- Trial name
- Quantiferon (NCT03916497)
- Testing
- Quantiferon CMV
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
CMV, EBV
Cytotoxic T Cells to Prevent Virus Infections
In this study, investigators are trying to see if infusion of "m-CTLs" will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection after cord blood transplant.
- Conditions
- CMV, EBV, Adenovirus Infections
- Trial name
- NCT01923766
- Testing
- Cytotoxic T lymphocytes (CTLs).
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's National Research Institute
CMV Infection
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
Cytomegalovirus (CMV) infections remain an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HSCT) recipients, especially in patients received haploidentical transplantation.
- Trial name
- NCT02985775
- Testing
- Donor-derived CMVpp65-specific T cells
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Peking University People's Hospital
CMV
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with human cellular proteins and…
- Trial name
- CMV-ICU (NCT04280380)
- Testing
- Real time PCR
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fundación de investigación HM
CMV
Effect of Atorvastatin on Subclinical Atherosclerosis
Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect.
- Trial name
- NCT04101136
- Where
- Indonesia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Congenital Cytomegalovirus (CMV)
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births.
- Trial name
- GANCIMVEAR (NCT02606266)
- Testing
- Valganciclovir
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Transplant Recipients With CMV Infection
A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5% of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol studies.
- Trial name
- ORPHAVIC (NCT02067169)
- Testing
- CMV Infection
- Where
- 38 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Limoges